Related Experiment Video

Updated: Mar 25, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

10.2K

Future options of anti-angiogenic cancer therapy

Yihai Cao1,2,3

  • 1Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, 171 77, Stockholm, Sweden. yihai.cao@ki.se.

Chinese Journal of Cancer
|February 17, 2016
PubMed

Insights

Anti-angiogenic drugs targeting tumor vessel growth show modest survival benefits in cancer patients. Understanding why these drugs differ in preclinical models versus humans is key to developing better cancer treatments.

Area of Science:

  • Oncology
  • Cancer Biology
  • Pharmacology

Background:

  • Anti-angiogenic drugs targeting tumor vessel growth are standard cancer treatments.
  • Clinical trials show modest survival benefits for these therapies.
  • Discrepancies exist between preclinical anti-angiogenic drug efficacy and human patient outcomes.

Purpose of the Study:

  • To explore the reasons behind the varied effects of anti-angiogenic drugs.
  • To discuss mechanisms of different anti-angiogenic drugs.
  • To outline future strategies for optimizing cancer treatment regimens.

Main Methods:

  • Review of clinical trial data for anti-angiogenic therapies.
  • Analysis of preclinical studies on anti-angiogenic drug mechanisms.
  • Discussion of potential reasons for efficacy disparities.

Main Results:

  • Anti-angiogenic therapies provide modest survival benefits in human cancer patients.
  • Significant differences in drug effects are observed between preclinical models and human patients.
  • The exact mechanisms driving these dissimilar effects remain unclear.

Conclusions:

  • Further research is needed to reconcile discrepancies in anti-angiogenic drug efficacy.
  • Optimizing treatment regimens requires a deeper understanding of drug mechanisms.
  • Future strategies should focus on improving patient outcomes through tailored anti-angiogenic therapies.

More Related Videos

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay09:03

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay

Published on: June 30, 2023

1.8K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

8.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
7.6K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K